COVID-19 Vaccines and therapeutics
DOI:
https://doi.org/10.32792/jeps.v13i2.303Abstract
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that first appeared in
Wuhan, China, gave rise to the coronavirus disease 2019 (COVID-19), a highly contagious and
pathogenic viral infection. COVID-19 is not currently being treated with a specific therapy. Remdesivir is
the first medication to be approved by the Food and Drug Administration (FDA) to treat COVID-19.
However, numerous alternative therapy modalities are being looked for as COVID-19 therapies. As part
of this review, we discussed the development of various drugs, their mechanism of action, and how they
might be applied to different cases of COVID-19 patients. This review also offers an update on the
development of novel COVID-19 preventive or therapeutic vaccines. We aimed to include the most
recent published data from phase III trials about various COVID-19 vaccines and include clinical data
made available on networks or peer-reviewed journals in addition to vaccines approved by the Food and
Drug Administration (FDA) or The World Health Organization (WHO).
References
Rothan, H.A., Byrareddy, S.N.,( 2020). The epidemiology and pathogenesis of coronavirus disease
(COVID-19) outbreak. J. Autoimmun. 109, 102433.
Arabi, Y.M., Murthy, S., Webb, S.,( 2020). COVID-19: a novel coronavirus and a novel challenge for
critical care. Intensive Care Med. 1–4.
Zhang, L., Liu, Y., (2020). Potential interventions for novel coronavirus in China: a systemic review. J.
Med. Virol. 92, 479–490.
Gorbalenya, A.E.,( 2020). Severe Acute Respiratory Syndrome-related Coronavirus–The Species and
Its Viruses, a Statement of the Coronavirus Study Group. Available:. BioRxiv.
Biswas, A., Bhattacharjee, U., Chakrabarti, A.K., Tewari, D.N., Banu, H., Dutta, S., (2020).
Emergence of novel coronavirus and COVID-19: whether to stay or die out? Crit. Rev. Microbiol. 46,
–193.
Worldometers, (2022). COVID live [Online]. Available: https://www.worldometers. info/coronavirus/.
R.M. Chugh, P. Bhanja, A. Norris, S. Saha, (2021). Experimental models to study COVID- 19 effect
in stem cells, Cells 10 (1) 91..
Han S. Clinical vaccine development. Clin Exp Vaccine Res. (2015) 4:46–53. doi:
7774/cevr.2015.4.1.46.
Singh K, Mehta S. (2016).The clinical development process for a novel preventive vaccine: an
overview. J Postgrad Med 62:4–11. doi: 10.4103/0022-3859.173187.
Basads EN VEC-Tores DE adenovirus son Seguras, Bien.( 2020). Toleradas INMUNÓ- GENA,
AEP, Aeplas Vacunas Contra EL SARS-COV-2. (COVID-19)
https://vacunasaep.org/profesionales/noticias/COVID- 19-vacunas-adenovirus-oxford1.
WHO. (2021). COVID19 VACCINE TRACKER https://covid19. trackvaccines.org/agency/who/.
https://www.cdc.gov/coronavirus/2019-ncov/vaccines/index.html. (2021).Developing COVID-19
VaccinesCOVID-19, Centers of Disease Control and Prevention.
D. Christensen. (2016). Vaccine adjuvants: why and how, Hum. Vaccin. Immunother. 12 (10) 2709–
, doi: 10.1080/21645515.2016.1219003.
B. Sanders, M. Koldijk, H. Schuitemaker, (2014). Inactivated viral vaccines, Vaccine Anal. 45–80,
doi: 10.1007/978-3-662-45024-6_2 .
A.B. Vogel, I. Kanevsky, Y. Che, K.A. Swanson, A. Muik, M. Vormehr, ,… K.C. et al., (2021).
BNT162b vaccines protect rhesus macaques from SARS-CoV-2, Nature 592 (7853) 283–289, doi:
1038/s41586-021-03275-y .
R.W. Frenck Jr, N.P. Klein, N. Kitchin, A. Gurtman, et al., . . . (2021). Ö. Türeci, C4591001 Clinical
Trial Group, Safety, immunogenicity, and efficacy of the BNT162b2 Covid-19 vaccine in adolescents,
New Eng. J. Med. 385 (3) 239–250, doi: 10.1056/NEJMoa2107456 .
https://www.PFIZER.COM/NEWS/PRESS-RELEASE/PRESS-RELEASE-DETAIL/PFIZER Pfizer
web. (2021) PFIZER AND BIONTECH ANNOUNCE POSITIVE TOPLINE RESULTS FROM
PIVOTAL TRIAL OF COVID-19 VACCINE IN CHILDREN 5 TO 11 YEARS.
J. Liu, Y. Liu, H. Xia, J. Zou, S.C. Weaver, K.A. Swanson, H. Cai, M. Cutler, …et al., (2021)
BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants, Na-ture 596 (7871) 273275, doi: 10.1038/s41586-021-03693.
https://www.modernatx.com, (2021) Moderna’s Work on our COVID-19 Vaccine.. Available from:
/modernas-work-potential-vaccine-against-covid-19.
S.E. Oliver, J.W. Gargano, M. Marin, M. Wallace, K.G. Curran, …. et al., (2021). The Advisory
committee on immunization practices’ interim recommendation for use of moderna COVID-19 Vaccine -
United States, December 2020, MMWR Morb. Mortal. Wkly. Rep. 69 (5152) 1653–16561.
L. Chu, R. McPhee, W. Huang, H. Bennett, R. Pajon, B. Nestorova, B. Leav, (2021). mRNA- 1273
Study Group, A preliminary report of a randomized controlled phase 2 trial of the safety and
immunogenicity of mRNA-1273 SARS-CoV-2 vaccine, Vaccine 39 (20) 2791–2799.
H.M. El Sahly, L.R. Baden, B. Essink, S. Doblecki-Lewis, J.M. Martin, …. et al., (2021). Efficacy
of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase, New Eng. J. Med. (2021)
NEJMoa2113017.
Wouters, O.J., Shadlen, K.C., Salcher-Konrad, M., Pollard, A.J., Larson, H.J., ( 2021). Challenges in
ensuring global access to COVID- 19 vaccines: production, affordability, allocation, and deployment.
Lancet 397, 1023–1034.
Alam, S., Kamal, T., Sarker, M., Zhou, J., Rahman, S., Mohamed, I.J.F.I.P., Org, W.F.,( 2021).
Therapeutic effectiveness and safety of repurposing drugs for the treatment of COVID-19:. Pharmacol.
, 659577 https://doi.org/ 10.3389/fphar.2021.659577.12.
Gurung, A.B., Ali, M.A., Lee, J., Farah, M.A., Al-Anazi, K.M.,( 2021). An updated review of
computer-aided drug design and its application to COVID-19. Biomed. Res. Int. 2021, 8853056.
Lu, H., (2020). Drug treatment options for the 2019-new coronavirus (2019-nCoV). Biosci. Trends
, 69–71.
Chen, X., Li, R., Pan, Z., Qian, C., Yang, Y., You, R., Zhao, J., Liu, P., Gao, L., ….et al., (2020).
Human monoclonal antibodies block the binding of SARS-CoV-2 spike protein to angiotensin converting
enzyme 2 receptor. Cell Mol. Immunol. 17, 647–649.
Administration, U.S.F.A.D., (2021). Emergency Use Authorization 100 [Online]. Available:
Emergency Use Authorization, 100.
Downloads
Published
Issue
Section
License
Copyright (c) 2023 Journal of Education for Pure Science- University of Thi-Qar
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright Policy
Authors retain copyright of their articles published in the Journal of Education for Pure Science (JEPS).
By submitting their work, authors grant the journal a non-exclusive license to publish, distribute, and archive the article in all formats and media.
License
All articles published in JEPS are licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0).
This license permits unrestricted use, distribution, and reproduction in any medium, provided that the original author(s) and the source are properly credited.
Author Rights
Authors have the right to:
-
Share their articles on personal websites, institutional repositories, and academic platforms
-
Reuse their work in future research and publications
-
Distribute the published version without restriction
Journal Rights
The journal retains the right to:
-
Publish and archive the articles
-
Include them in indexing and archiving systems such as LOCKSS and CLOCKSS
-
Promote and disseminate the published work
Responsibility
The contents of all articles are the sole responsibility of the authors. The journal, editors, and editorial board are not responsible for any errors, opinions, or statements expressed in the published articles.
Open Access Statement
JEPS provides immediate open access to its content, supporting the principle that making research freely available to the public enhances global knowledge exchange.
This work is licensed under a Creative Commons Attribution 4.0 International License.
https://creativecommons.org/licenses/by/4.0/
